What is the role of mutation testing in a postmenopausal woman with endometrial (ca endometrium) cancer?

Mutation Testing in Endometrial Cancer

All newly diagnosed endometrial cancers should undergo universal tumor testing for DNA mismatch repair (MMR) deficiency using immunohistochemistry, regardless of patient age, family history, or tumor histology, to identify Lynch syndrome and guide treatment decisions. 1, 2

Primary Testing Algorithm

Universal MMR Testing (Required for All Cases)

• Perform immunohistochemical staining for all four MMR proteins (MLH1, MSH2, MSH6, PMS2) on every endometrial cancer specimen as part of routine pathologic examination 1, 2
• This testing serves dual purposes: identifying Lynch syndrome carriers (who require genetic counseling and cascade family testing) and providing prognostic information that influences adjuvant therapy decisions 1, 2
• Testing can be performed on initial biopsy, dilation and curettage material, or final hysterectomy specimen 1

MLH1-Specific Reflex Testing

• When MLH1 loss is detected on immunohistochemistry, immediately perform MLH1 promoter methylation testing to distinguish sporadic from hereditary causes 1, 2
• Methylated MLH1 indicates sporadic (epigenetic) cancer and does not require germline genetic testing 1, 2
• Non-methylated MLH1 loss mandates genetic counseling and germline mutation testing for Lynch syndrome 1, 2
• This critical step prevents unnecessary germline testing in the majority of MLH1-deficient cases (which are sporadic) while identifying the minority requiring hereditary cancer evaluation 2

Additional Molecular Testing for Risk Stratification

• Perform POLE exonuclease domain mutation testing in all non-low-risk endometrial cancers (intermediate, high-intermediate, high risk, or advanced disease) 1, 2
• Test for aberrant p53 expression to identify copy number high (serous-like) tumors, which represent the most aggressive subtype requiring multimodality treatment including chemotherapy 1
• Consider comprehensive genomic profiling via validated/FDA-approved assay to facilitate cancer diagnosis and identify potential therapeutic targets 1

Clinical Management Based on Testing Results

For MMR-Deficient Tumors (Non-Methylated)

• Women with confirmed Lynch syndrome face 30-60% lifetime risk of endometrial cancer and require intensive surveillance 1, 2
• Initiate annual endometrial biopsy starting at age 35 years for unaffected relatives with Lynch syndrome 1, 2
• Recommend prophylactic hysterectomy and bilateral salpingo-oophorectomy after childbearing completion, ideally by age 40 1, 2
• Institute annual colonoscopy for colorectal cancer surveillance 1, 2
• Provide genetic counseling for cascade testing of at-risk family members 1

For POLE-Mutated Tumors

• These tumors may appear high-grade with deep myometrial invasion and lymphovascular space invasion but typically have excellent prognosis 1
• POLE mutation status may influence decisions regarding adjuvant therapy de-escalation 1

For p53-Aberrant Tumors

• Copy number high subtype represents the most aggressive form requiring multimodality treatment, almost always including chemotherapy 1
• This molecular classification supersedes traditional histologic grading in determining treatment intensity 1

Critical Pitfalls to Avoid

Testing Errors

• Never skip MLH1 methylation testing when MLH1 loss is detected—this single test distinguishes sporadic from hereditary cases and prevents unnecessary germline testing in the majority of patients 2
• Do not accept normal tumor MMR testing as definitively excluding Lynch syndrome in patients with strong family history—9.5% of germline mutation carriers have tumor testing suggesting sporadic cancer 2
• Do not limit MMR testing to young patients or those with family history—universal testing identifies 28% more Lynch syndrome cases than selective testing strategies 1

Surveillance Errors

• For women with Lynch syndrome, yearly endometrial biopsy enables early detection and allows fertility preservation by deferring surgery until childbearing is complete 1
• Annual outpatient hysteroscopy with endometrial sampling in Lynch syndrome patients has high diagnostic accuracy for detecting endometrial cancer and atypical hyperplasia 1

Family Implications

• Failure to identify Lynch syndrome in the proband denies at-risk relatives the opportunity for cancer prevention through surveillance and prophylactic surgery 1
• Relatives with Lynch syndrome but without endometrial cancer benefit from annual endometrial biopsy to enable early detection while preserving fertility 1

Integration with Traditional Pathology

• The complete molecular classification (combining MMR status, p53 status, POLE mutation status, and traditional pathologic parameters) provides reproducible, prognostically relevant classification that guides adjuvant treatment decisions 2
• This integrated genomic-pathologic approach improves risk stratification beyond traditional histopathologic features alone 1, 2
• Molecular classification is particularly valuable when morphologic assessment is challenging or when traditional features provide conflicting prognostic information 1